Literature DB >> 20961112

Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants.

Lee W Tremblay1, Hua Xu, John S Blanchard.   

Abstract

The genome of Mycobacterium tuberculosis (TB) contains a gene that encodes a highly active β-lactamase, BlaC, that imparts TB with resistance to β-lactam chemotherapy. The structure of covalent BlaC-β-lactam complexes suggests that active site residues K73 and E166 are essential for acylation and deacylation, respectively. We have prepared the K73A and E166A mutant forms of BlaC and have determined the structures of the Michaelis complex of cefamandole and the covalently bound acyl intermediate of cefamandole at resolutions of 1.2 and 2.0 Å, respectively. These structures provide insight into the details of the catalytic mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961112      PMCID: PMC2981129          DOI: 10.1021/bi1015088

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  22 in total

1.  Structural basis for imipenem inhibition of class C beta-lactamases.

Authors:  Beth M Beadle; Brian K Shoichet
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 2.  Beta-lactamases: a survey of protein diversity.

Authors:  Marion S Helfand; Robert A Bonomo
Journal:  Curr Drug Targets Infect Disord       Date:  2003-03

Review 3.  Formation of the glycan chains in the synthesis of bacterial peptidoglycan.

Authors:  J van Heijenoort
Journal:  Glycobiology       Date:  2001-03       Impact factor: 4.313

Review 4.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

5.  Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem.

Authors:  Lee W Tremblay; Fan Fan; John S Blanchard
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

6.  Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.

Authors:  Michiyosi Nukaga; Christopher R Bethel; Jodi M Thomson; Andrea M Hujer; Anne Distler; Vernon E Anderson; James R Knox; Robert A Bonomo
Journal:  J Am Chem Soc       Date:  2008-08-30       Impact factor: 15.419

7.  Inhibition of class A and class C beta-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate.

Authors:  Michiyoshi Nukaga; Takao Abe; Aranapakam M Venkatesan; Tarek S Mansour; Robert A Bonomo; James R Knox
Journal:  Biochemistry       Date:  2003-11-18       Impact factor: 3.162

8.  Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution.

Authors:  Matthew Kalp; Paul R Carey
Journal:  Biochemistry       Date:  2008-10-16       Impact factor: 3.162

Review 9.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  The 1.4 A crystal structure of the class D beta-lactamase OXA-1 complexed with doripenem.

Authors:  Kyle D Schneider; Mary E Karpen; Robert A Bonomo; David A Leonard; Rachel A Powers
Journal:  Biochemistry       Date:  2009-12-22       Impact factor: 3.162

View more
  18 in total

1.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

2.  Withdrawn

Authors: 
Journal:  Infect Disord Drug Targets       Date:  2012-11-16

3.  Crystal structures of β-1,4-galactosyltransferase 7 enzyme reveal conformational changes and substrate binding.

Authors:  Yuko Tsutsui; Boopathy Ramakrishnan; Pradman K Qasba
Journal:  J Biol Chem       Date:  2013-09-19       Impact factor: 5.157

4.  Crystal structure of a preacylation complex of the β-lactamase inhibitor sulbactam bound to a sulfenamide bond-containing thiol-β-lactamase.

Authors:  Elizabeth A Rodkey; Sarah M Drawz; Jared M Sampson; Christopher R Bethel; Robert A Bonomo; Focco van den Akker
Journal:  J Am Chem Soc       Date:  2012-09-26       Impact factor: 15.419

5.  Crystallographic Snapshots of Class A β-Lactamase Catalysis Reveal Structural Changes That Facilitate β-Lactam Hydrolysis.

Authors:  Xuehua Pan; Yunjiao He; Jinping Lei; Xuhui Huang; Yanxiang Zhao
Journal:  J Biol Chem       Date:  2017-01-18       Impact factor: 5.157

6.  Mechanisms of proton relay and product release by Class A β-lactamase at ultrahigh resolution.

Authors:  Eric M Lewandowski; Kathryn G Lethbridge; Ruslan Sanishvili; Joanna Skiba; Konrad Kowalski; Yu Chen
Journal:  FEBS J       Date:  2017-11-20       Impact factor: 5.542

7.  Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from Mycobacterium tuberculosis.

Authors:  Carmen Chow; Hua Xu; John S Blanchard
Journal:  Biochemistry       Date:  2013-05-30       Impact factor: 3.162

8.  Enantioselective C-H Olefination of α-Hydroxy and α-Amino Phenylacetic Acids by Kinetic Resolution.

Authors:  Kai-Jiong Xiao; Ling Chu; Jin-Quan Yu
Journal:  Angew Chem Int Ed Engl       Date:  2016-01-22       Impact factor: 15.336

9.  Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.

Authors:  Sebastian G Kurz; Kerstin A Wolff; Saugata Hazra; Christopher R Bethel; Andrea M Hujer; Kerri M Smith; Yan Xu; Lee W Tremblay; John S Blanchard; Liem Nguyen; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

10.  NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis.

Authors:  Hua Xu; Saugata Hazra; John S Blanchard
Journal:  Biochemistry       Date:  2012-05-22       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.